help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaisson, R. E.
Right arrow Articles by Halsey, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaisson, R. E.
Right arrow Articles by Halsey, N. A.

Am. J. Respir. Crit. Care Med., Vol 154, No. 4, Oct 1996, 1034-1038.

Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection

RE Chaisson, HC Clermont, EA Holt, M Cantave, MP Johnson, J Atkinson, H Davis, R Boulos, TC Quinn and NA Halsey
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

We enrolled 427 consecutive patients with tuberculosis diagnosed in Cite Soleil, Haiti in a trial of short-course intermittent therapy. All patients received supervised therapy with isoniazid, rifampin, pyrazinamide, and ethambutol thrice weekly for 8 wk, followed by isoniazid and rifampin thrice weekly for 18 wk. At entry, the 177 human immunodeficiency virus (HIV)-infected patients (42%) were found significantly more likely to have extrapulmonary tuberculosis and negative tuberculin skin tests (p < 0.05). Treatment was well tolerated by both groups of patients, and adherence to the treatment regimen was over 90%. Among patients with pulmonary or intrathoracic tuberculosis, 9% of HIV-seropositive and 1% of HIV-seronegative patients died during therapy (p < 0.001), whereas 81% and 87%, respectively, of those in the two groups were cured. Relapses occurred in 5.4% of HIV-seropositive and 2.8% of HIV-seronegative patients who completed treatment (p = 0.36). Survival after tuberculosis was poorer in HIV-seropositive patients, whose probability of dying was 33% at 18 mo after diagnosis as compared with 3% for HIV-seronegative patients (p < 0.001). HIV- seropositive patients who died had significantly lower median CD4 lymphocyte counts than did HIV-seropositive patients who survived (p < 0.001). Treatment of tuberculosis with short-course, thrice-weekly, supervised therapy in the setting of a developing country is highly efficacious in both HIV-seropositive and -seronegative patients.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Nahid, L. C. Gonzalez, I. Rudoy, B. C. de Jong, A. Unger, L. M. Kawamura, D. H. Osmond, P. C. Hopewell, and C. L. Daley
Treatment Outcomes of Patients with HIV and Tuberculosis
Am. J. Respir. Crit. Care Med., June 1, 2007; 175(11): 1199 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. Ribera, C. Azuaje, R. M. Lopez, P. Domingo, A. Curran, M. Feijoo, L. Pou, P. Sanchez, M. A. Sambeat, J. Colomer, et al.
Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis
J. Antimicrob. Chemother., April 1, 2007; 59(4): 690 - 697.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al.
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy.
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Jasmer, L. Bozeman, K. Schwartzman, M. D. Cave, J. J. Saukkonen, B. Metchock, A. Khan, W. J. Burman, and the Tuberculosis Trials Consortium
Recurrent Tuberculosis in the United States and Canada: Relapse or Reinfection?
Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1360 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M.D. Iseman
Tuberculosis therapy: past, present and future
Eur. Respir. J., July 1, 2002; 20(36_suppl): 87S - 94s.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. J. BURMAN and B. E. JONES
Treatment of HIV-related Tuberculosis in the Era of Effective Antiretroviral Therapy
Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 7 - 12.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Lauzardo and D. Ashkin
Phthisiology at the Dawn of the New Century
Chest, May 1, 2000; 117(5): 1455 - 1473.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. M. FitzGerald and S. Houston
Tuberculosis: 8. The disease in association with HIV infection
Can. Med. Assoc. J., July 1, 1999; 161(1): 47 - 51.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
C MAYAUD and J CADRANEL
Tuberculosis in AIDS: past or new problems?
Thorax, July 1, 1999; 54(7): 567 - 571.
[Full Text]

Home page
 NEJMHome page
D. V. Havlir and P. F. Barnes
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1996 American Thoracic Society